- Avicanna (AVCN) and Santé Cannabis are initiating a real-world evidence study using RHO Phyto branded Cannabigerol transdermal gel
- The real-world evidence study will be conducted in Montréal, Quebec, with Santé Cannabis and will evaluate the efficacy of the product on patients with musculoskeletal pain and inflammation
- The RHO Phyto CBG Transdermal Gel contains 2 per cent Cannabidiol (CBD) and 1 per cent CBG
- Avicanna Inc. (AVCN) was down 7.89 per cent, trading at C$0.35 per share as of 1:45 pm ET
Avicanna (AVCN) and Santé Cannabis are initiating a real-world evidence study using RHO Phyto-branded Cannabigerol transdermal gel.
The real-world evidence study will be conducted in Montréal, Quebec, with Santé Cannabis and will evaluate the efficacy of the product on patients with musculoskeletal pain and inflammation.
One hundred patients will be enrolled to test the efficacy of the RHO Phyto CBG Transdermal Gel containing 2 per cent Cannabidiol (CBD) and 1 per cent CBG on arthritis, including osteoarthritis, rheumatoid arthritis, fibromyalgia, muscle and/or joint pain, localized pain, post-surgical pain, muscular and/or structural injuries.
This three-month study will be conducted by Santé Cannabis, an independent medical cannabis clinic and research services provider. Santé Cannabis has developed a data collection platform and centred model in executing its role as a CRS and CRO. The prospective study is expected to launch in early Q1 2023.
Dr. Michael Dworkind, Medical Director of Santé Cannabis and Associate Professor of McGill University, called the exploration of novel topical formulations “very exciting” to the clinical team as products may provide patients with localized pain relief while avoiding systemic effects and side effects altogether.
“We are so pleased to work with Avicanna to assess the effectiveness of their RHO Phyto CBG Transdermal Gel, to shed light on the very understudied field of cannabinoid-based topical products.”
Dr. Karolina Urban, Vice President of Scientific and Medical Affairs, added that Santé Cannabis has built a comprehensive registry database for conducting real-world evidence studies.
“With the initiation of the study, we will further demonstrate our ongoing dedication to researching, developing, and making available evidence-based products to patients and the medical community.”
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments.
Avicanna Inc. (AVCN) was down 7.89 per cent, trading at C$0.35 per share as of 1:45 pm ET.
